Event in Progress:
Discover the latest content that has just been published on Research Tree
Thanks to the sugar segment, Suedzucker astounded the market by again raising its FY 2024 operating result outlook. The consensus warrants an upward revision. Amidst a challenging landscape, the sugar segment continues to command attention. The prevailing macroeconomic challenges firmly position volumes at the heart of numerous discussions
Companies: Suedzucker AG
AlphaValue
The sugar segment and prices were in the spotlight during the impressive first quarter. The operating results rose by +73% yoy, and the margin stood at a high level of 11.2%. The market warmly welcomed (stock price up by c.+6.50% in the early afternoon) the upward revision of the outlook, which comes as no surprise to us, as we had discussed a few weeks ago.
While last month’s trading update was warmly received by the market, this time it has been a cold shower for the stock price, with a significant decline of 7.20%. Despite the elevated price level, we are concerned about the possibility of Suedzucker back-pedaling on its outlook.
A strong performance in sugar drove the Q3 figures (finally!). The FY22/23 guidance was reiterated on the back of an improving environment despite the obvious cost pressure.
The Q2 continued to show an overall improvement in the group’s business, even prompting SZU to revise up its revenue guidance. On the other hand, costs are starting to weigh. No upgrade to the EBIT and EBITDA guidance.
The recovery is still on track in a sugar market which has been and will continue to be favourable for the company.
Sugar’s on-track recovery boosted (and will continue) the top line, leading to a FY21/22 sales guidance upgrade. However, as it is not immune from cost inflation (especially energy) and having less-pricing power than other consumer staples, Sueduzcker maintains its previous operating profit guidance.
No major surprise as the group confirmed the preliminary figures, as well as the FY21/22 guidance. No update about the 2026 strategy, which is not expected for now, and this makes the stock somewhat boring at the moment.
The turnaround in the sugar business is firm which is expected to drive the top and bottom line positively in the coming years. However, the strategy up to 2026 given today does not seem clear and needs to be clarified in the future, especially in quantitative terms.
Although the group shows improving results, especially due to strong comparables, the disappointing sugar outlook is a black spot. The company maintained its FY guidance only by offsetting the weakness in sugar by non-sugar products.
No major surprises in Suedzucker’s Q1 results, as the company already provided an update last month. The group reiterated its FY20/21 guidance. However, we maintain our expectations in its low range due to the fact that it currently does not take into account the COVID-19 impact.
Good FY19 figures, but the recovery is expected to be halted by the COVID-19 crisis, which is expected to weigh on sugar and ethanol prices.
9m results were in line with expectations and guidance reiterated. While the sugar segment’s revenues fell sharply, the fruit segment’s held steady at last year’s level and the special products and CropEnergies segments’ rose. It was a bit of a disappointment when the company said the recent recovery in sugar prices isn’t yet enough to earn money in the sugar segment.
In a favourable environment, with worldwide sugar contract prices growing, the (second) increase in guidance should be interpreted positively by the market. Confidence is definitely returning to the stock.
Suedzucker increased its operating result outlook due to the further very positive ethanol market environment. We are likely to raise our estimates for FY19/20.
Research Tree provides access to ongoing research coverage, media content and regulatory news on Suedzucker AG. We currently have 0 research reports from 1 professional analysts.
Companies: Premier Foods plc
Shore Capital
Companies: Genus plc
Liberum
The second full year of Greggs’ five-year growth plan to double revenue by FY26 should be marked down as very successful, especially so given the challenging external environment. Unlike many consumer-facing companies, high selling price inflation was accompanied by volume growth, leading to good market share gains. The consumer is responding well to new initiatives to grow revenue in new dayparts and digital channels. Profitability was well-managed with better recovery of input cost inflation t
Companies: Greggs plc
Edison
Carr’s Group has announced an updated strategy that offers the potential for value realisation and creation from a number of avenues. These include: value realisation of the Engineering Division; the ability to significantly reduce central costs; and longer-term value creation in the Agriculture Division as a focused business with recovery potential and a strategy to leverage its strong market positions for growth.
Companies: Carr's Group PLC
We are reiterating our Buy rating, projections and $22.50 price target for Betterware de Mexico with the company announcing 1Q24 (March) results after the close on Thursday. We believe, with momentum returning at the Betterware division, JAFRA remaining on a new product and marketing focus, the United States market becoming a larger emphasis and BWMX continuing to offer a compelling (and secure) dividend yield of 8.5%, BWMX remains well positioned to reward investors on multiple levels, and we r
Companies: NUS MED NUS BWMX MED DDMX
Small Cap Consumer Research LLC
The Hardman & Co Healthcare Index (HHI) has been running since 2009. Its main function is to highlight the attractions of life sciences investments over the long term. For the second year running, apart from global economic influences affecting world markets, performance in 2023 was dented by the capital-intensive nature of the sector. The HHI fell 3.7%, to 483.8, underperforming the main London markets – FTSE 100 (+3.8%) and FTSE All-Share (3.8%) but outperforming the FTSE AIM All-Share Index (
Companies: TXG NDVA TSVT BCOW Z29 TXG NCYT GNS SUN AMS OMG APH EKF EAH IMM AGL DEMG AGY TSTL IPO GDR ETX TRX HVO CTEC AVO OXB DEST VLG IXI VAL INDV AGR AVCT BAI 123F IMCR BCOW
Hardman & Co
We are reiterating our Buy rating, $22.50 price target and projections for Betterware de Mexico after reviewing the March catalog. March completed a 1Q with material YoY positives, from higher SKU counts, rising cadence of new and debuting products, a return of key favorites and continued reductions in overall discounting levels. We believe Betterware management has been able to capitalize on the return to normalcy for their supply chain to roll out compelling new items, offer normalized pricing
11 January 2023 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment object
Companies: NICL DELT COG ABDP PYC W7L WSBN KIBO CRTA
Hybridan
20th March 2024 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment object
Companies: CTL EKF IQG ANP SML VRS EQLS POLB
Companies: TXP CRPR SNX ARBB TON FA/ SBRY MTW BWNG HFG HUW UJO MOTR OBD NRR DEST CBOX SDX EYE FDM EPWN SAVE W7L ACRL FAR BVC MWE MATD SENX
Companies: Anpario plc
Companies: OHT TIDE ELCO TSTL VEL BBSN
Cavendish
Companies: OHT PCIP SND CORA
Share: